Novzan disclosed that the 2022 semi -annual report achieved a revenue of 1.620 billion yuan

On August 25, Norvan (code: 688105.SH) released the 2022 semi -annual performance report.

From January 1, 2022-June 30, 2022, the company realized operating income of 1.620 billion yuan, an increase of 96.20%year-on-year, and net profit was 614 million yuan, an increase of 56.67%year-on-year, and the basic earnings per share were 1.53 yuan.

The company's industry is biological products.

During the company's reporting period, the total assets at the end of the period were 5.469 billion yuan, the operating profit was 703 million yuan, the accounts receivable were 493 million yuan, and the net cash flow generated by operating activities was 131 million yuan.Cash is 1.561 billion yuan.

Nuo Weizan, the company's full name is Nanjing Nuowazan Biotechnology Co., Ltd., established on March 16, 2012. The current general manager Cao Lin. The main business is functional protein and high molecular organic materials around enzymes, antigens, antibodies and other functional proteins.Carry out technical research and development and product development.

- END -